Outpatient testing must not be encouraged, promoted or advertised. Persons with COVID-like illness not requiring hospitalization should be instructed to stay home. It is safer for the patients and health care workers and testing does not cu

Co-Diagnostics has been part of the coronavirus conversation for the past two months. Whether its been educating the public about the disease or developing diagnostics for the virus, the company has been at the forefront. Now the Salt Lake

Following reports that hydroxychloroquine and chloroquine are under evaluation in clinical trials as a potential treatment of COVID-19, drug companies are donating doses and planning for ramping up supply. Bayer announced in aMarch 19, 2020

Abbott Laboratories, one of the biggest players in the medical device space, has obtained Emergency Use Authorization for a test to detect the coronavirus [COVID-19]. The Abbott Park, IL-based company joins the rapidly expanding list of com

Illumina has filed a lawsuit against BGI Group subsidiary Latvia MGI Tech in the Dsseldorf Regional Court in Germany, alleging that BGIs sequencing products and related reagents infringe a patent Illumina holds in Europe, EP 1 530 578 B1, w

Abbott announced today that it has received CE marking for its Alinity m molecular diagnostics system and assays, which are now available in countries that recognize the designation. The firm said that its molecular system will help clinici

Indiana University School of Medicine researchers have developed a test to measure pain pain in patients. The hope is that such a test could help in the fight against opioid abuse. The study was led by Alexander Niculescu, MD, PhD and was pu

C2N Diagnostics is experiencing a couple of breakthroughs with its Alzheimers disease detection test - one courtesy of FDA. The agency, which is slowly rising back to full strength after the temporary government shutdown, granted the St. Lou

Day Zero Diagnostics (DZD) is seeking to develop a more effective way of detecting infectious disease using artificial intelligence and genome sequencing. The Boston-based company announced it has raised $8.6 million in its mission to furthe

French diagnostics firm Novacyt announcedrecentlythat it has received CE marking for its Genesig BK virus (BKV) and Epstein-Barr virus (EBV) diagnostic kits, which are designed for use in post-transplantation and immunosuppressed patients. B